On November 3, 2022 IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on the creation and development of IgM antibodies, and ADC Therapeutics SA (NYSE:ADCT) reported that they have signed a collaboration and supply agreement to evaluate the combination of imvotamab, the novel bispecific IgM antibody, engaging T cells and targeting CD20 and CD3 proteins, d ‘IGM, and ZYNLONTA (loncastuximab tesirine-lpyl), CD19-targeting antibody-drug conjugate (ADC) from ADC Therapeutics, for the treatment of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) ( R/R) (Press release, IGM Biosciences, NOV 3, 2022, View Source [SID1234623020]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
" Patients with B-cell non-Hodgkin’s lymphoma (NHL) need effective and well-tolerated treatments," said Chris Takimoto, MD, Ph.D., FACP, Chief Medical Officer at IGM Biosciences. " We welcome this collaboration with ADC Therapeutics to provide a novel combination therapy targeting both CD19 and CD20 expressing cells for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). We look forward to working with the ADC Therapeutics team and starting the clinical trial in the first quarter of 2023."
According to data presented at the 2021 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, imvotamab indicated 50% complete response (CR) at the likely optimal dose of 100 mg (n=10). Among the 28 patients treated in the current dose-adjusted cohorts, cytokine release syndrome was observed in <20% of patients.
" We are excited to collaborate with IGM Biosciences to explore ZYNLONTA in combination with imvotamab," said Joseph Camardo, MD, Chief Medical Officer of ADC Therapeutics. " This collaboration extends ADC Therapeutics’ commitment to maximizing the potential of our CD19-targeting ADC for patients with significant unmet medical needs, both as a single agent and in novel combinations with other anti-cancer agents. The safety profile of imvotamab and the activity observed so far in phase 1 are promising for future development. »
Under the terms of the agreement, IGM will be responsible for conducting the clinical trial to evaluate the safety and efficacy of imvotamab in combination with ZYNLONTA in the treatment of patients with R/R NHL. ADC Therapeutics will provide clinical expertise regarding ZYNLONTA and supply the drug for the trial. IGM expects to start the trial in the first quarter of 2023. The clinical collaboration is based on compelling mechanistic analysis and preclinical data showing activity of this approach.